← Back to headlines
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - Taiwan News
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity Taiwan News
19 Mar, 22:30 — 19 Mar, 22:30
Related Stories
Iloilo Reinstates Health Protocols Amid Extreme Heat
just now
Four arrested for selling P102 million in fake anti-cancer medicines in Makati
just now
Vigilance Urged After Death of Two Children in Abandoned Car
just now
Long Waiting Lists for Pediatric Eye Doctors in Latvia Lead to Unborn Child Registrations
just now